Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| T-Therapeutics | Cambridge | Series B | $133.0M | 2026-11-05 |
| DISCO Pharmaceuticals | Cologne | Seed | $42.3M | 2025-12-11 |
| Kainova Therapeutics | Montréal | Series B | $23.5M | 2026-02-09 |
| Mironid | Glasgow | Series B | $45.9M | 2026-08-05 |
| GlycoEra | Wädenswil | Series B | $130.0M | 2025-05-27 |
| Betteromics | Redwood City | Series A | $20.0M | 2023-10-26 |
| Bon Vivant | Lyon | Series A | $29.4M | 2026-02-24 |
| Synthace | London | Series C | $35.0M | 2021-11-16 |
8 rows of the CSV in 5 of its 18 columns.
- The 35 Sofinnova Partners portfolio companies have raised $1.6B in total.
- 5 of them closed their most recent round in the last 12 months, $274.1M combined.
- The largest of those rounds is T-Therapeutics' $133.0M Series B, dated November 2026.
- Bpifrance is an investor in 4 of them, more than any other fund.
- Biotech is the most common sector, with 19 companies (54%).
- 26% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (60% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
17 of 35| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow, United Kingdom | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| Bon Vivant | Bon Vivant uses precision fermentation to produce real dairy products accessible to everyone. | Biotech | Lyon, France | Series A | $29.4M | 2026-02-24 | $59.6M | Kima Ventures, Picus Capital, Sofinnova Partners +1 | 11 to 50 | 2021 |
| Kainova Therapeutics | Kainova Therapeutics develops therapies that modulate GPCRs to treat immuno-oncology and inflammatory conditions. | Biotech | Montréal, Canada | Series B | $23.5M | 2026-02-09 | $123.6M | Bpifrance, Sofinnova Partners, Andera Partners +1 | 11 to 50 | 2001 |
| DISCO Pharmaceuticals | DISCO Pharmaceuticals performs large-scale surfaceome mapping of cancer cells to find drug targets. | Health care | Cologne, Germany | Seed | $42.3M | 2025-12-11 | $64.0M | Sofinnova Partners, M Ventures, AbbVie +1 | 11 to 50 | 2022 |
| Qorium | Qorium makes reinvented real leather materials. | Biotech | Maastricht, The Netherlands | Series A | $25.5M | 2025-11-11 | $28.6M | Sofinnova Partners, Brightlands Venture Partners | 11 to 50 | 2021 |
| ENYO Pharma | ENYO Pharma is a biopharmaceutical company based in Lyon, France. | Biotech | Lyon, France | Series C | $7.0M | 2025-06-12 | $108.8M | Bpifrance, OrbiMed, Sofinnova Partners +2 | 11 to 50 | 2014 |
| GlycoEra | GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. | Biotech | Wädenswil, Switzerland | Series B | $130.0M | 2025-05-27 | $179.3M | Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 | 11 to 50 | 2020 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Basel, Switzerland | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| deepc | deepc provides an AI operating system for radiology. | Artificial intelligence | Munich, Germany | Series A | $13.0M | 2024-07-25 | $26.0M | VentureOut, Sofinnova Partners, Bertelsmann Investments +2 | 11 to 50 | 2019 |
| EndoRon Medical | EndoRon Medical develops an endovascular suture-like device for treating abdominal aortic aneurysm. | Health care | Kfar Saba, Israel | Series A | $10.0M | 2024-07-09 | European Innovation Council, MedTech Innovator, Sofinnova Partners | 1 to 10 | 2019 | |
| Betteromics | BetterOmics provides a SaaS platform with AI and computational tools for life sciences professionals. | Artificial intelligence | Redwood City, United States | Series A | $20.0M | 2023-10-26 | $20.0M | Sofinnova Partners, SHAKTI, Triatomic Capital | 11 to 50 | 2020 |
| Sitryx Therapeutics | Sitryx Therapeutics develops disease-modifying therapeutics in immuno-oncology and immuno-inflammation. | Biotech | Oxford, United Kingdom | Series A | $39.0M | 2023-09-27 | Sofinnova Partners, Oxford Science Enterprises, SV Health Investors +1 | 11 to 50 | 2018 | |
| Gradient Denervation Technologies | Gradient Denervation Technologies develops a transvascular medical device for treating pulmonary hypertension. | Biotech | Paris, France | Series A | $15.0M | 2023-09-07 | MedTech Innovator, Sofinnova Partners, Thuja Capital +1 | 11 to 50 | 2019 | |
| POLYNEURON | Polyneuron is a pharmaceutical company developing a new drug class for autoimmune disorders. | Biotech | Basel, Switzerland | Series A | $15.4M | 2020-09-16 | $45.0M | New Enterprise Associates, Venture Kick, Sofinnova Partners +1 | 1 to 10 | 2014 |
| Sensitive Object | Sensitive Object develops electronic products for consumer electronics, home automation, and interactive digital advertising. | Hardware | Boulogne-billancourt, France | Series B | $6.0M | 2009-12-03 | Sofinnova Partners, Motorola Solutions Venture Capital | 1 to 10 | 2003 | |
| PregLem | PregLem is a Swiss biopharmaceutical company that develops and commercializes new drugs. | Biotech | Geneva, Switzerland | Series B | $32.2M | 2007-12-04 | $58.2M | Sofinnova Partners, Sofinnova Investments, MVM Life Science Partners +1 | 11 to 50 | 2006 |
Table 1. Sofinnova Partners portfolio companies: the 17 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 35.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| 2 | Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow, United Kingdom | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| 3 | DISCO Pharmaceuticals | DISCO Pharmaceuticals performs large-scale surfaceome mapping of cancer cells to find drug targets. | Health care | Cologne, Germany | Seed | $42.3M | 2025-12-11 | $64.0M | Sofinnova Partners, M Ventures, AbbVie +1 | 11 to 50 | 2022 |
| 4 | Bon Vivant | Bon Vivant uses precision fermentation to produce real dairy products accessible to everyone. | Biotech | Lyon, France | Series A | $29.4M | 2026-02-24 | $59.6M | Kima Ventures, Picus Capital, Sofinnova Partners +1 | 11 to 50 | 2021 |
| 5 | Kainova Therapeutics | Kainova Therapeutics develops therapies that modulate GPCRs to treat immuno-oncology and inflammatory conditions. | Biotech | Montréal, Canada | Series B | $23.5M | 2026-02-09 | $123.6M | Bpifrance, Sofinnova Partners, Andera Partners +1 | 11 to 50 | 2001 |
Table 2. Sofinnova Partners portfolio companies: the 5 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Bpifrance | Government investment office | Maisons-alfort, France | 4 | 11% | 1 | Kainova Therapeutics |
| 2 | Sofinnova Investments | Venture capital firm | Menlo Park, United States | 3 | 9% | ||
| 3 | Andera Partners | Private equity firm | Paris, France | 2 | 6% | 1 | Kainova Therapeutics |
| 4 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 2 | 6% | ||
| 5 | MedTech Innovator | Startup accelerator | Los Angeles, United States | 2 | 6% | ||
| 6 | Ventech | Venture capital firm | Paris, France | 2 | 6% | ||
| 7 | Partners Group | Private equity firm | Baar, Switzerland | 2 | 6% | ||
| 8 | Earlybird Venture Capital | Venture capital firm | Berlin, Germany | 2 | 6% | ||
| 9 | University of Cambridge Enterprise | University program | Cambridge, United Kingdom | 1 | 3% | 1 | T-Therapeutics |
| 10 | Digitalis Ventures | Venture capital firm | New York, United States | 1 | 3% | 1 | T-Therapeutics |
| 11 | F-Prime | Venture capital firm | Cambridge, United States | 1 | 3% | 1 | T-Therapeutics |
| 12 | Cambridge Innovation Capital | Venture capital firm | Cambridge, United Kingdom | 1 | 3% | 1 | T-Therapeutics |
| 13 | AbbVie | Corporate venture arm | North Chicago, United States | 1 | 3% | 1 | DISCO Pharmaceuticals |
| 14 | Panakes Partners | Venture capital firm | Milan, Italy | 1 | 3% | 1 | DISCO Pharmaceuticals |
| 15 | M Ventures | Corporate venture arm | Amsterdam, The Netherlands | 1 | 3% | 1 | DISCO Pharmaceuticals |
Table 3. Sofinnova Partners portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 19 | 54% | $1.4B |
| Health care | 19 | 54% | $1.4B |
| Software | 15 | 43% | $157.2M |
| Artificial intelligence | 4 | 11% | $64.0M |
| Hardware | 4 | 11% | $20.0M |
| Commerce | 1 | 3% | |
| Cybersecurity | 1 | 3% | |
| Fintech | 1 | 3% | $55.0M |
Table 4. Sofinnova Partners portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Sofinnova Partners portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| France | 12 | 34% |
| Switzerland | 6 | 17% |
| United Kingdom | 5 | 14% |
| United States | 5 | 14% |
| Germany | 3 | 9% |
| Canada | 1 | 3% |
| The Netherlands | 1 | 3% |
| Spain | 1 | 3% |
| Israel | 1 | 3% |
Table 6. Sofinnova Partners portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Sofinnova Partners portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 20% | $133.0M |
| August 2026 | 1 | 20% | $45.9M |
| February 2026 | 2 | 40% | $52.9M |
| December 2025 | 1 | 20% | $42.3M |
Table 8. Sofinnova Partners portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 11% | $231.8M |
| 2025 | 4 | 11% | $204.7M |
| 2024 | 8 | 23% | $343.9M |
| 2023 | 5 | 14% | $91.9M |
| 2021 | 1 | 3% | $35.0M |
| 2020 | 1 | 3% | $15.4M |
Table 9. Sofinnova Partners portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 9 | 26% |
| 2015 to 2019 | 10 | 29% |
| 2010 to 2014 | 4 | 11% |
| Before 2010 | 12 | 34% |
Table 10. Sofinnova Partners portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 7 | 20% |
| 11 to 50 | 21 | 60% |
| 51 to 100 | 6 | 17% |
| 101 to 250 | 1 | 3% |
Table 11. Sofinnova Partners portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Sofinnova Partners is recorded as one of its investors. On 16 November 2026 that is 35 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 17 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 35 rows: 0 have no round amount, 0 no city and 9 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Sofinnova Partners portfolio companies are on the list?
- 35, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 35 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.